In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...
Pharmaceutical Technology on MSN2d
FDA approves AstraZeneca’s Imfinzi combo for bladder cancerThe US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...
Zacks Investment Research on MSN2d
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer IndicationAstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...
Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...
The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.
Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.
Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback